MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41586-020-3035-9

Медицинская библиотека · Nature · 2020

A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate.

Sanchez-Felipe Lorena, Vercruysse Thomas, Sharma Sapna, Ma Ji, Lemmens Viktor, Van Looveren Dominique, Arkalagud Javarappa Mahadesh Prasad, Boudewijns Robbert, Malengier-Devlies Bert, Liesenborghs Laurens, Kaptein Suzanne J F, De Keyzer Carolien, Bervoets Lindsey, Debaveye Sarah, Rasulova Madina, Seldeslachts Laura, Li Li-Hsin, Jansen Sander, Yakass Michael Bright, Verstrepen Babs E, Böszörményi Kinga P, Kiemenyi-Kayere Gwendoline, van Driel Nikki, Quaye Osbourne, Zhang Xin, Ter Horst Sebastiaan, Mishra Niraj, Deboutte Ward, Matthijnssens Jelle, Coelmont Lotte, Vandermeulen Corinne, Heylen Elisabeth, Vergote Valentijn, Schols Dominique, Wang Zhongde, Bogers Willy, Kuiken Thijs, Verschoor Ernst, Cawthorne Christopher, Van Laere Koen, Opdenakker Ghislain, Vande Velde Greetje, Weynand Birgit, Teuwen Dirk E, Matthys Patrick, Neyts Johan, Jan Thibaut Hendrik, Dallmeier Kai

СтатьяПоддержка исследования: вне правительства СШАПеревод требует повторной обработки

Аннотация

The expanding pandemic of coronavirus disease 2019 (COVID-19) requires the development of safe, efficacious and fast-acting vaccines. Several vaccine platforms are being leveraged for a rapid emergency response1. Here we describe the development of a candidate vaccine (YF-S0) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that uses live-attenuated yellow fever 17D (YF17D) vaccine as a vector to express a noncleavable prefusion form of the SARS-CoV-2 spike antigen. We assess vaccine safety, immunogenicity and efficacy in several animal models. YF-S0 has an excellent safety profile and induces high levels of SARS-CoV-2 neutralizing antibodies in hamsters (Mesocricetus auratus), mice (Mus musculus) and cynomolgus macaques (Macaca fascicularis), and-concomitantly-protective immunity against yellow fever virus. Humoral immunity is complemented by a cellular immune response with favourable T helper 1 polarization, as profiled in mice. In a hamster model2 and in macaques, YF-S0 prevents infection with SARS-CoV-2. Moreover, a single dose conferred protection from lung disease in most of the vaccinated hamsters within as little as 10 days. Taken together, the quality of the immune responses triggered and the rapid kinetics by which protective immunity can be attained after a single dose warrant further development of this potent SARS-CoV-2 vaccine candidate.

Для цитирования: Sanchez-Felipe Lorena, Vercruysse Thomas, Sharma Sapna, Ma Ji, Lemmens Viktor, Van Looveren Dominique, Arkalagud Javarappa Mahadesh Prasad, Boudewijns Robbert, Malengier-Devlies Bert, Liesenborghs Laurens, Kaptein Suzanne J F, De Keyzer Carolien, Bervoets Lindsey, Debaveye Sarah, Rasulova Madina, Seldeslachts Laura, Li Li-Hsin, Jansen Sander, Yakass Michael Bright, Verstrepen Babs E, Böszörményi Kinga P, Kiemenyi-Kayere Gwendoline, van Driel Nikki, Quaye Osbourne, Zhang Xin, Ter Horst Sebastiaan, Mishra Niraj, Deboutte Ward, Matthijnssens Jelle, Coelmont Lotte, Vandermeulen Corinne, Heylen Elisabeth, Vergote Valentijn, Schols Dominique, Wang Zhongde, Bogers Willy, Kuiken Thijs, Verschoor Ernst, Cawthorne Christopher, Van Laere Koen, Opdenakker Ghislain, Vande Velde Greetje, Weynand Birgit, Teuwen Dirk E, Matthys Patrick, Neyts Johan, Jan Thibaut Hendrik, Dallmeier Kai. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate.. Nature. 2020. DOI: 10.1038/s41586-020-3035-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.